Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Curr Opin Urol ; 30(4): 507-512, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32427629

RESUMEN

PURPOSE OF REVIEW: To provide an overview of available electrical stimulation devices in neurogenic patients with lower urinary tract disease. RECENT FINDINGS: It is advocated to do more studies in neurogenic patients as results seem promising and useful but most studies did not include neurogenic patients or neurogenic patients were not analyzed or reported separately. Most studies included a small heterogenous neurogenic group with multiple pathophysiologic origin focusing on effect of a treatment instead of results of a treatment in a specific neurogenic group. Neuromodulation or stimulation has the advantage that it acts on different organs, like bladder and bowel, so can treat neurogenic patients, who mostly suffer from multiple organ failure. SUMMARY: Brindley procedure, sacral neuromodulation (SNM) and posterior tibial nerve stimulation (PTNS) are available for a while already. The Brindley procedure (including sacral anterior root stimulation in combination with a rhizotomy of posterior sacral roots) is developed for selected spinal cord injury patient with a complete spinal injury, and has shown results for many years in neurogenic patients. An alternative to the rhizotomy is not established yet. SNM and PTNS are other modalities that are used in nonneurogenic patients, but are not yet indicated and much studied in neurogenic patients.


Asunto(s)
Terapia por Estimulación Eléctrica/métodos , Rizotomía , Nervio Tibial , Vejiga Urinaria Neurogénica/terapia , Vejiga Urinaria/inervación , Desnervación , Estimulación Eléctrica , Terapia por Estimulación Eléctrica/efectos adversos , Humanos , Neuroestimuladores Implantables , Síntomas del Sistema Urinario Inferior/fisiopatología , Síntomas del Sistema Urinario Inferior/terapia , Región Sacrococcígea , Raíces Nerviosas Espinales/fisiopatología , Raíces Nerviosas Espinales/cirugía , Vejiga Urinaria Neurogénica/etiología
2.
Urologe A ; 58(4): 437-450, 2019 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-30923856

RESUMEN

The spectrum of surgical procedures for the minimally invasive treatment of benign prostatic hyperplasia (BPH) has significantly increased over the last two decades. The simple suprapubic prostatectomy (subtotal prostatectomy, SP) has largely lost relevance in current practice. On the other hand, transurethral resection of the prostate (TURP) has been further standardized and potentially made safer by the introduction of the bipolar technique and low-pressure systems.Transurethral (endoscopic) enucleation techniques (endoscopic enucleation of the prostate, EEP) are increasingly competing with the current gold standard TURP and are replacing SP for treatment of larger adenomas. This approach is especially related to the rapid development of laser technology, which has sustainably changed the face of modern BPH treatment in a similar way to stone therapy. This has been incorporated in the clinical patient management, clinical studies and standardization of numerous surgical techniques that are systematically described in this article. Additionally, efforts have also been made to use other energy sources, such as bipolar current in EEP. With respect to scientific objectivity, high-quality clinical trials are regularly published which further strengthen the position of EEP.


Asunto(s)
Terapia por Láser , Hiperplasia Prostática , Resección Transuretral de la Próstata , Endoscopía , Humanos , Masculino , Prostatectomía , Hiperplasia Prostática/terapia
3.
Urologe A ; 51(12): 1692-6, 2012 Dec.
Artículo en Alemán | MEDLINE | ID: mdl-23160608

RESUMEN

The established treatment of neurogenic lower urinary tract dysfunction (NLUTD) in patients with spinal cord injury (SCI) or meningomyelocele (MMC) is mainly conservative and is aimed at the lower urinary tract. For example, oral antimuscarinic medication is the standard treatment of neurogenic detrusor overactivity. Recently, however, treatment aiming directly or indirectly at the innervation of the urinary tract has gained increasing attention. Current evidence does not justify the use of nerve rerouting but the existing preliminary data are more promising for MMC patients than for those with SCI. Sacral neuromodulation is already a therapeutic option for incomplete SCI patients. Initial data from a pilot study indicate that in patients with complete SCI implementation in the spinal shock phase may prevent the development of NLUTD. Licensing of onabotulinum toxin A (Botox®) facilitated its clinical use for treating NLUTD but it is limited to the indication of neurogenic detrusor overactivity incontinence with a dosage of 200 IU. The mentioned unconventional treatments, although discussed controversially, are promising future treatment options for NLUTD.


Asunto(s)
Terapias Complementarias/métodos , Terapias Complementarias/tendencias , Terapia por Estimulación Eléctrica/métodos , Meningomielocele/terapia , Antagonistas Muscarínicos/uso terapéutico , Paraplejía/terapia , Vejiga Urinaria Neurogénica/terapia , Humanos , Meningomielocele/complicaciones , Paraplejía/complicaciones , Vejiga Urinaria Neurogénica/etiología
4.
Urologe A ; 49(2): 245-52, 2010 Feb.
Artículo en Alemán | MEDLINE | ID: mdl-19859688

RESUMEN

The syndrome of idiopathic overactive bladder (I-OAB) impairs quality of life for the affected individuals. Conservative treatment options such as antimuscarinics are not always effective, and resulting side effects can lead the patient to stop treatment. In recently years, minimally invasive and reversible sacral neuromodulation and botulinum toxin A have become available. Currently, the approved treatment option for I-OAB that is recommended by the International Consultation on Incontinence is sacral neuromodulation by InterStim therapy. This article gives an overview of the present clinical evidence on the effectiveness and reliability of these two treatment modalities as well as the current significance of sacral neuromodulation and botulinum toxin A for the second-line treatment of adult I-OAB.


Asunto(s)
Toxinas Botulínicas Tipo A/uso terapéutico , Terapia por Estimulación Eléctrica , Fármacos Neuromusculares/uso terapéutico , Vejiga Urinaria Hiperactiva/terapia , Toxinas Botulínicas Tipo A/administración & dosificación , Toxinas Botulínicas Tipo A/efectos adversos , Toxinas Botulínicas Tipo A/farmacología , Humanos , Neuroestimuladores Implantables , Inyecciones , Músculo Liso/efectos de los fármacos , Fármacos Neuromusculares/administración & dosificación , Fármacos Neuromusculares/efectos adversos , Fármacos Neuromusculares/farmacología , Región Sacrococcígea , Vejiga Urinaria Hiperactiva/tratamiento farmacológico
5.
Prog Urol ; 19(8): 530-7, 2009 Sep.
Artículo en Francés | MEDLINE | ID: mdl-19699450

RESUMEN

The overactive bladder syndrome (OAB) negatively affects the daily life of many people worldwide and conservative treatments, such as antimuscarinics, not always bring relief and/or are associated with considerable side effects resulting in treatment failure. Second line treatment options used to be invasive surgical procedures. However, less radical, minimally invasive and reversible alternatives, such as sacral neuromodulation and botulinum toxin A have emerged. Of these, only sacral neuromodulation with InterStim Therapy has been approved for OAB and been recommended by the International Consultation on Incontinence (ICI) in 2004. Nevertheless, depending of country rules and habits, both seem to be used by urologists in clinical practice for treating idiopathic OAB (I OAB). Therefore, this review attempts to provide an update on the available clinical evidence concerning the efficacy and safety, and the current position of sacral neuromodulation and botulinum toxin A in the second line management of adults with I OAB.


Asunto(s)
Vejiga Urinaria Hiperactiva/terapia , Toxinas Botulínicas Tipo A/uso terapéutico , Terapia por Estimulación Eléctrica , Humanos , Fármacos Neuromusculares/uso terapéutico
6.
J Urol ; 165(6 Pt 1): 2103-9, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11371936

RESUMEN

PURPOSE: We tested the hypothesis that transfecting penile tissue with brain derived neurotrophic factor may facilitate neural recovery and erectile capability after cavernous nerve injury. MATERIALS AND METHODS: Of the 34 Sprague-Dawley rats used 10 underwent sham operation and 24 underwent bilateral cavernous nerve freezing and intracavernous injection of adeno-associated virus-LacZ (12) or adeno-associated virus-brain derived neurotrophic factor (12). Erectile function was assessed by cavernous nerve electrostimulation at 4 and 8 weeks, and samples of penile tissue and the major pelvic ganglia were evaluated histologically. RESULTS: In the brain derived neurotrophic factor group mean maximal intracavernous pressure plus or minus standard deviation was significantly higher than in the LacZ group at 4 and 8 weeks (58.5 +/- 11.7 cm. water versus 28.4 +/- 5.5 and 61.3 +/- 12.5 versus 37.7 +/- 7.9, respectively). In addition, in the brain derived neurotrophic factor group reduced nicotinamide adenine dinucleotide phosphate diaphorase staining and neuronal nitric oxide synthase immunostaining revealed significantly more positive nerve fibers in the dorsal nerves and cavernous tissue than in the LacZ group at each time point and the percent of neuronal nitric oxide synthase positive neurons in the major pelvic ganglia was also significantly greater. Moreover, in the LacZ group most neurons showed a light staining pattern with irregular contours and numerous vacuoles in the cytoplasm. CONCLUSIONS: Intracavernous injection of adeno-associated virus-brain derived neurotrophic factor may prevent the degeneration of neuronal nitric oxide synthase containing neurons in the major pelvic ganglia and facilitate the regeneration of neuronal nitric oxide synthase containing nerve fibers in penile tissue, thus, enhancing the recovery of erectile function after bilateral cavernous nerve injury.


Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/metabolismo , Dependovirus , Modelos Animales de Enfermedad , Disfunción Eréctil/terapia , Transfección , Animales , Masculino , NADPH Deshidrogenasa , Proteínas del Tejido Nervioso/fisiología , Óxido Nítrico Sintasa/fisiología , Óxido Nítrico Sintasa de Tipo I , Pene/inervación , Ratas , Ratas Sprague-Dawley , Regeneración/fisiología
7.
J Urol ; 165(5): 1755-9, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11342970

RESUMEN

PURPOSE: We evaluated the time dependence of smooth muscle regeneration and restoration of in vivo functional properties in bladder augmented with a bladder acellular matrix graft. MATERIALS AND METHODS: A total of 45 Sprague-Dawley rats underwent augmentation cystoplasty with a bladder acellular matrix graft. Two rats each were sacrificed at various intervals within the first 21 days and 6 each were sacrificed at 4, 8 and 12 weeks. This second group underwent preoperative and postoperative assessment of bladder function, including cystometry, electrostimulation and stimulation with ice water, potassium and carbachol, as well as labeling of the bladder wall by the injection of fluorescent microspheres. After sacrifice slides of the bladders prepared for hematoxylin and eosin, trichrome, KI67, vimentin, desmin, smooth muscle specific alpha-actin and fluorescent microspheres were evaluated. RESULTS: Within 2 weeks the number of cells in the matrix as well as the proliferation index increased rapidly and then decreased gradually. Erythrocytes and inflammatory cells were found in the matrix within 2 to 4 days, followed by fibroblasts. A bladder host-to-matrix shift was evident by the appearance of microspheres in the matrix. Cell marker expression indicated the early appearance of vimentin and alpha-actin within the first 10 days. Distinct desmin expression was observed later, when the first smooth muscle cells were recognized. Functional evaluation revealed restored bladder function at 12 weeks. CONCLUSIONS: The time dependent increase of muscle cell markers during smooth muscle cell regeneration in a bladder acellular matrix graft is concordant with the progressive restoration of bladder function. These results may support the bladder acellular matrix graft concept for clinical application.


Asunto(s)
Materiales Biocompatibles , Colágeno , Implantes Experimentales , Músculo Liso/citología , Regeneración , Vejiga Urinaria/citología , Vejiga Urinaria/cirugía , Actinas/análisis , Animales , Desmina/análisis , Femenino , Antígeno Ki-67/análisis , Músculo Liso/química , Ratas , Ratas Sprague-Dawley , Factores de Tiempo , Vejiga Urinaria/química , Vejiga Urinaria/fisiología , Urodinámica , Vimentina/análisis
8.
J Urol ; 164(5): 1798-801, 2000 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11025772

RESUMEN

PURPOSE: We examine the effect of a Chinese herbal medicine mixture on erectile function in a rat model of hypercholesterolemic erectile dysfunction. MATERIALS AND METHODS: In this study 32, 3-month-old Sprague-Dawley rats were used. The 8 control animals were fed a normal diet and the remaining 24 were fed 1% cholesterol diet for 4 months. After 2 months herbal medicine was added to the drinking water of the treatment group of 16 rats but not the cholesterol only group of 8. Of the 16 rats 8 received 25 mg./kg. per day (group 1) and 8 received 50 mg./kg. per day (group 2) of Chinese herbal medicine mixture. Serum cholesterol levels were measured at 2 and 4 months. At 4 months erectile function was evaluated with cavernous nerve electrostimulation in all animals. Penile tissues were collected for electron microscopy, and to perform Western blot for endothelial nitric oxide synthase, neuronal nitric oxide synthase, basic fibroblast growth factor (bFGF) and caveolin-1. RESULTS: Serum cholesterol levels were significantly higher in animals fed the 1% cholesterol diet compared to controls at 2 and 4 months. Nevertheless, there was no significant difference among group 1 (145 +/- 30 mg./dl.), group 2 (157 +/- 20) and the cholesterol only group (143 +/- 15). Systemic arterial pressure was not significantly different between the animals that were fed the 1% cholesterol diet and the controls. During electrostimulation of the cavernous nerve peak sustained intracavernous pressure was significantly lower in the cholesterol only group (50 +/- 23 cm. H2O) compared to the control group. Conversely erectile function was not impaired in the herbal medicine treated rats. Electron microscopy showed many caveolae with fingerlike processes in the cavernous smooth muscle and endothelial cell membranes in control and treated rats but not in the cholesterol only group of rats. Western blot did not show a difference among groups in protein expression for endothelial nitric oxide synthase and neuronal nitric oxide synthase in penile tissue but caveolin-1 and bFGF protein expression was significantly higher in groups 1 and 2 than in the cholesterol only and control groups. CONCLUSIONS: Rats developed erectile dysfunction after being fed a 1% cholesterol diet for 4 months. Although serum cholesterol levels were similar in the cholesterol only rats and those treated with Chinese herbal medicine mixture, erectile response was significantly better in the treated group. The mechanism of the herbal medicine is unknown. High levels of bFGF and caveolin-1 expression in the treated group may protect the cavernous smooth muscle and endothelial cells from the harmful effect of high serum cholesterol.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Erección Peniana/efectos de los fármacos , Animales , Western Blotting , Caveolina 1 , Caveolinas/metabolismo , Modelos Animales de Enfermedad , Disfunción Eréctil/etiología , Disfunción Eréctil/prevención & control , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Hipercolesterolemia/complicaciones , Masculino , Proyectos Piloto , Ratas , Ratas Sprague-Dawley
9.
Urologe A ; 39(6): 535-8, 2000 Nov.
Artículo en Alemán | MEDLINE | ID: mdl-11138272

RESUMEN

Up to now there is no specific treatment targeting the ultimate cause of interstitial cystitis (IC), since its pathogenesis and etiology are still unknown. Most studies focussing on oral medication have not been randomized, double-blinded or placebo-controlled. Numerous case reports and intent-to-treat trials are lacking a systematic approach and do not meet evidence-based medicine criteria. Consequently there is as yet no standard oral therapy available for the treatment of IC. However, only a few oral substances have shown a potential to improve symptoms such as frequency and pain. The best results were obtained from monotherapeutic use of pentosanpolysulfate, amitriptylin and hydroxycin. The true benefit of these substances alone should be compared to analgesics and anticholinergics in the course of controlled clinical trials.


Asunto(s)
Cistitis Intersticial/tratamiento farmacológico , Administración Oral , Amitriptilina/administración & dosificación , Analgésicos/administración & dosificación , Antiinflamatorios/administración & dosificación , Cistitis Intersticial/etiología , Humanos , Hidroxizina/administración & dosificación , Poliéster Pentosan Sulfúrico/administración & dosificación , Esteroides , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA